Αποτελέσματα Αναζήτησης
The Ova1Plus report calculates a personalized risk score by combining biomarker measurements (including CA-125), menopausal status, and ultrasound results. CA-125 is included in the panel of the biomarkers and will be included on the results report.
The OVA1 algorithm combines the results of these levels with information on the menopause status of the patient to classify the patient into a low- or high-risk group. The results of the OVA1 test can help determine patients needing referral to a gynecologic oncologist for their surgery.
Ova1 ® is a qualitative serum test that combines the results of five immunoassays into a single numerical result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist.
8 Ιαν 2013 · A low-risk OVA1 test result correctly predicted the absence of malignancy by 98 percent. The authors concluded that the OVA1 test is a useful blood test to check prior to surgery performed by general gynecologist.
13 Οκτ 2009 · OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiologic test results fail to indicate malignancy.
22 Μαΐ 2023 · Results: Among 290 low-risk OVA1 patients, 99.0% remained benign for 12 months compared with 97.2% of 181 low-risk CA125 patients.
16 Οκτ 2013 · OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical result. The tests include: CA125 (increased in ovarian tumors) Apolipoprotein A1 (decreased in ovarian tumors) Beta-2 microglobulin (increased in ovarian tumors) Transferrin (decreased in ovarian tumors) Pre-albumin (decreased in ovarian ...
